These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3708620)

  • 1. Phase II trial of N-methylformamide for advanced renal cell carcinoma.
    Sternberg CN; Yagoda A; Scher HI; Hollander P
    Cancer Treat Rep; 1986 May; 70(5):681-2. PubMed ID: 3708620
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II trial of N-methylformamide in advanced renal cancer.
    Abrams JS; Tait N; Silva H; Eisenberger M; Van Echo DA; Olver IN; Aisner J
    Am J Clin Oncol; 1989 Feb; 12(1):41-2. PubMed ID: 2912020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-methylformamide-induced hypophosphatemia.
    Sternberg CN; Yagoda A
    Cancer Treat Rep; 1985 Mar; 69(3):343-4. PubMed ID: 3978663
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase I trial of N-methylformamide (NMF, NSC 3051).
    O'Dwyer PJ; Donehower M; Sigman LM; Fortner CL; Aisner J; Van Echo DA
    J Clin Oncol; 1985 Jun; 3(6):853-7. PubMed ID: 4009219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of N-methylformamide in patients with advanced colorectal cancer.
    Tchekmedyian NS; Kaplan RS; Eisenberger M; Abrams J; Van Echo D
    Cancer Treat Rep; 1987 May; 71(5):541-2. PubMed ID: 3567980
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase II trial of N-methylformamide in patients with advanced colorectal carcinoma.
    Tauer K; Kemeny N; Cheng E; Hollander P; Geller N
    Cancer Treat Rep; 1986 Jun; 70(6):813-4. PubMed ID: 3524831
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase I study of N-methylformamide in patients with advanced cancer.
    Ettinger DS; Orr DW; Rice AP; Donehower RC
    Cancer Treat Rep; 1985 May; 69(5):489-93. PubMed ID: 4005871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of N-methylformamide.
    McVie JG; ten Bokkel Huinink WW; Simonetti G; Dubbelman R
    Cancer Treat Rep; 1984 Apr; 68(4):607-10. PubMed ID: 6325001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of pyrazoloacridine in metastatic renal cell carcinoma.
    Kuebler JP; King GW; Triozzi P; Moore T; Kraut EH
    Invest New Drugs; 2001; 19(4):327-8. PubMed ID: 11561693
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II trial of elliptinium in advanced renal cell carcinoma.
    Caillé P; Mondesir JM; Droz JP; Kerbrat P; Goodman A; Ducret JP; Theodore C; Spielman M; Rouëssé J; Amiel JL
    Cancer Treat Rep; 1985; 69(7-8):901-2. PubMed ID: 4016798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of N-methylformamide in advanced head and neck cancer.
    Vogel WC; Forastiere AA; Natale RB; Takasugi BJ; Schnur G
    Invest New Drugs; 1987; 5(2):203-6. PubMed ID: 3654153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer.
    Ettinger DS; Finkelstein DM; Abeloff MD; Chang YC; Smith TJ; Oken MM; Ruckdeschel JC
    Invest New Drugs; 1990 May; 8(2):183-5. PubMed ID: 2166720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II evaluation of mitoxantrone in advanced renal cell carcinoma: a Southeastern Cancer Study Group Trial.
    Gams RA; Nelson O; Birch R
    Cancer Treat Rep; 1986 Jul; 70(7):921-2. PubMed ID: 3521848
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib].
    Xie XD; Piao Y; Liu ZZ
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):714-5. PubMed ID: 20021872
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II study of lonidamine in patients with metastatic renal cell carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study.
    Weinerman BH; Eisenhauer EA; Besner JG; Coppin CM; Stewart D; Band PR
    Cancer Treat Rep; 1986 Jun; 70(6):751-4. PubMed ID: 3524824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I-II trial of gallium nitrate for advanced hypernephroma.
    Schwartz S; Yagoda A
    Anticancer Res; 1984; 4(4-5):317-8. PubMed ID: 6486736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A Case of Renal Cell Carcinoma with High Everolimus Blood Concentrations and Hyperglycemia Due to Everolimus-Induced Hepatic Dysfunction].
    Takasaki S; Kikuchi M; Kawasaki Y; Ito A; Arai Y; Yamaguchi H; Mano N
    Gan To Kagaku Ryoho; 2017 Jan; 44(1):87-89. PubMed ID: 28174388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity of oral N-methylformamide in three phase II trials: a report from the National Cancer Institute of Canada Clinical Trials Group.
    Eisenhauer EA; Weinerman BH; Kerr I; Quirt I
    Cancer Treat Rep; 1986 Jul; 70(7):881-3. PubMed ID: 3719579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of streptozocin in the treatment of advanced renal cell carcinoma.
    Licht JD; Garnick MB
    Cancer Treat Rep; 1987 Jan; 71(1):97-8. PubMed ID: 2947680
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma.
    Shaheen PE; Stadler W; Elson P; Knox J; Winquist E; Bukowski RM
    Invest New Drugs; 2005 Dec; 23(6):577-81. PubMed ID: 16034517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.